Plasma clomipramine levels in adult patients with obsessive-compulsive disorder

被引:10
|
作者
Marazziti, Donatella [1 ]
Baroni, Stefano [1 ]
Faravelli, Luca [1 ]
Giannaccini, Gino [1 ]
Massimetti, Gabriele [1 ]
Palego, Lionella [1 ]
Catena-Dell'Osso, Mario [1 ]
机构
[1] Univ Pisa, Dipartimento Psichiatria Neurobiol Farmacol & Bio, I-56100 Pisa, Italy
关键词
clomipramine; drug metabolism; sex; high-performance liquid chromatography; obsessive-compulsive disorder; plasma levels; Yale-Brown Obsessive Compulsive Scale; DOUBLE-BLIND TRIAL; CLINICAL-RESPONSE; TRICYCLIC ANTIDEPRESSANTS; N-DESMETHYLCLOMIPRAMINE; LIQUID-CHROMATOGRAPHY; DEPRESSED-PATIENTS; DRUG; METAANALYSIS; METABOLITES; EFFICACY;
D O I
10.1097/YIC.0b013e32834cde39
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to explore the possible relationship between plasma clomipramine and its major metabolite (N-desmethylclomipramine) levels and related parameters, and clinical features in patients with obsessive-compulsive disorder (OCD). Twenty-six outpatients (13 men, 13 women), suffering from OCD were consecutively enrolled in this study. The severity of OCD was assessed by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). The measurements were taken after 4 weeks and 6 months from the beginning of the treatment. The drug levels were measured by a high-performance liquid chromatography method developed by us. The correlations between biological and clinical parameters were analyzed by means of Spearman's correlation coefficient. The Mann-Whitney test was used for comparing biological and clinical variables between men and women. The results showed that clomipramine levels were related to the doses at the two assessment times. A significant and positive correlation was detected at the beginning between the N-desmethylclomipramine ratio and the Y-BOCS total score; however, this was true only for men, where the similar correlations were measured also with the Y-BOCS subscale. After 6 months of clomipramine, men showed a significant improvement of the compulsions. These findings would highlight the potential impact of assessing clomipramine plasma levels and their relationships with specific symptoms, as well as the influence of the sex on the drug response. Int Clin Psychopharmacol 27:55-60 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:55 / 60
页数:6
相关论文
共 50 条
  • [21] THE CLOMIPRAMINE CHALLENGE TEST IN OBSESSIVE-COMPULSIVE DISORDER
    SAIZ, J
    LOPEZIBOR, JJ
    VINAS, R
    HERNANDEZ, M
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1992, 7 : 41 - 42
  • [22] Neurosteroid Levels in Patients with Obsessive-Compulsive Disorder
    Erbay, Lale Gonenir
    Kartalci, Sukru
    PSYCHIATRY INVESTIGATION, 2015, 12 (04) : 538 - 544
  • [23] Cytokine levels in patients with obsessive-compulsive disorder
    Gulpek, D.
    Gulseren, S.
    Capraz, N.
    Aksun, S.
    Topaloglu, B.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S621 - S621
  • [24] CLOMIPRAMINE - A TRICYCLIC ANTIDEPRESSANT EFFECTIVE IN OBSESSIVE-COMPULSIVE DISORDER
    KELLY, MW
    MYERS, CW
    DICP-THE ANNALS OF PHARMACOTHERAPY, 1990, 24 (7-8): : 739 - 744
  • [25] CONTROLLED COMPARISON OF BUSPIRONE AND CLOMIPRAMINE IN OBSESSIVE-COMPULSIVE DISORDER
    PATO, MT
    PIGOTT, TA
    HILL, JL
    GROVER, GN
    BERNSTEIN, S
    MURPHY, DL
    AMERICAN JOURNAL OF PSYCHIATRY, 1991, 148 (01): : 127 - 129
  • [26] CLOMIPRAMINE, CLONAZEPAM, AND CLONIDINE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
    HEWLETT, WA
    VINOGRADOV, S
    AGRAS, WS
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1992, 12 (06) : 420 - 430
  • [27] RETURN OF SYMPTOMS AFTER DISCONTINUATION OF CLOMIPRAMINE IN PATIENTS WITH OBSESSIVE-COMPULSIVE DISORDER
    PATO, MT
    ZOHARKADOUCH, R
    ZOHAR, J
    MURPHY, DL
    AMERICAN JOURNAL OF PSYCHIATRY, 1988, 145 (12): : 1521 - 1525
  • [28] Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder
    Zohar, J
    Judge, R
    Ait
    Alvarez, E
    Ansseau
    Arnoux, A
    Barbier, J
    Bardel
    Barrere, J
    Bartholome, F
    Bejerot, S
    Bernon
    Bimes
    Blauwblomme
    Bollen, J
    Bonnaffoux, D
    BonnetGuerin, B
    Braccini
    Cervera, S
    Coste
    Cottraux
    deBleeker, E
    Bradwejn, J
    deBuck
    deNayer, AR
    deWilde, J
    DHaenen
    Dijkstra, H
    Ditzler, K
    Faruch, M
    Faroux, C
    Freeman, C
    Hand, I
    Hantouche
    Haziza, L
    Healy, D
    Kasper, S
    Khalifa
    Klein, E
    Kulik, J
    Leibovici, A
    Lepine
    Marmin
    Moles, MF
    Note, I
    Notten, P
    Nutzinger, D
    ODonoghue, F
    Osterheider, M
    Parmentier, G
    BRITISH JOURNAL OF PSYCHIATRY, 1996, 169 (04) : 468 - 474
  • [29] CLOMIPRAMINE TREATMENT OF POSSIBLE ATYPICAL OBSESSIVE-COMPULSIVE DISORDER
    CAMERON, OG
    WASIELEWSKI, P
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1990, 10 (05) : 375 - 376
  • [30] FENFLURAMINE AUGMENTATION OF CLOMIPRAMINE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
    JUDD, FK
    CHUA, P
    LYNCH, C
    NORMAN, T
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 1991, 25 (03): : 412 - 414